Atossa Therapeutics, Inc.
ATOS
NASDAQ·Healthcare·Biotechnology·Mkt cap $25.1M
$2.52
▼ -0.40%
P/E
—
Mkt Cap
$25.1M
52-Wk Range
$1.70–$19.35
52-Week Range
$1.70 - $19.35
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 79.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary oral formulation of (Z)-endoxifen with improved bioavailability
- Focus on underserved women's oncology market
- Multi-modal therapeutic approach combining small molecules and immunotherapy
- Clinical-stage pipeline with multiple development programs
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Advancement of (Z)-endoxifen through Phase II clinical trials
Value
Valuation data unavailable
Momentum
Falling
-44.6% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying ATOS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 7, 2026
Reported EPS of -$0.95 vs -$1.02 consensus (+6.9% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+6.9%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Rodman & Renshaw · Jul 7, 2026
vs Industry
How ATOS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related